The legal library gives you easy access to the FTC’s case information and other official legal, policy, and guidance documents.
20160938: Coherent, Inc.; Rofin-Sinar Technologies Inc.
20160980: Compagnie De Saint-Gobain; Schenker-Winkler Holding AG
20161012: Brocade Communications Systems, Inc.; Ruckus Wireless, Inc.
Lupin Ltd., et al., In the Matter of
Generic drug manufacturers Lupin Ltd. and Gavis Pharmaceuticals LLC agreed to sell the rights and assets for two generic drugs, in order to settle FTC charges that Lupin’s proposed $850 million acquisition of Gavis would likely be anticompetitive.The merger would have combined two of only four companies that currently market generic doxycycline monohydrate capsules in two dosage strengths, used to treat bacterial infections, likely resulting in higher prices. The merger also would have eliminated one of only a few companies likely to enter the market for generic mesalamine extended release capsules, used to treat ulcerative colitis, in the near future, thereby delaying beneficial competition and the prospect of price decreases. Under the terms of the order, Lupin is required to transfer to G&W Laboratories all of Gavis’s rights and assets related to generic doxycycline monohydrate capsules no later than ten days after the acquisition is consummated. The order also requires that Gavis divest its rights and assets related to generic mesalamine capsules to G&W before the acquisition takes place.